Human epidermal growth factor receptor-2 is overexpressed in up to 30% of breast cancers; indicative of poor prognosis.
Immunotherapeutic approaches to treating cancer have been evaluated during the last few decades with limited success.
Although ADT remains an important treatment, its use as primary therapy in low-risk prostate cancer seems increasingly ill advised.
Biomarkers can provide great opportunities in the management of the most common HIV-associated malignancies, namely, Kaposi sarcoma, non-Hodgkin's lymphoma, and invasive cervical cancer.
Certain oral contraceptives may increase breast cancer risk, but researchers caution that the risk is small, if it exists at all.
18F-fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) is used to monitor treatment response after definitive (chemo)radiotherapy for head and neck squamous cell carcinoma, but its usefulness remains controversial.
Biomarker-driven chemotherapeutics is becoming a critical part of the state-of-the-art treatment in early- and late-phase clinical trials involving patients with T-cell lymphoma.
Diarrhea is a treatment symptom as common as hair loss but with deadlier implications.
Rate of cervical cancer in African-American women is higher than what was previously recognized.
The protocol was developed to guide clinicians who have limited medical intervention options.
Oncologists need more information on the factors that lead to nonadherence in order to actively prevent it.
There is still more work to be done to ensure that palliative care is understood.
ASCO recommendation tasks oncologists with assisting obese patients with cancer in finding appropriate resources for weight management.
Cancer care costs are becoming a significant problem; however, a new tool may help oncologists assess how patients will be affected by treatment expenses.
With the cost of cancer care rising, an ASCO task force has been established to create a framework for assessing relative value of cancer treatment.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|